Effect of chemokin polymorphisms on the efficacy of chemotherapy in patients with Her2/neu-negative breast cancer
Syvak L., Verovkina N., Lyalkin S., Tarasenko T., Martynyuk O.
Summary. Abstract. Today, the idea of personalized treatment of each individual patient depending on the sum of the biological characteristics of the tumor remains a topical issue in clinical oncology. Tumor cells and cells of the microenvironment synthesize various chemokines that act as growth factors, stimulators of angiogenesis and invasiveness, participate in the formation of immunosuppressive microenvironment. Aim — to study the CCR5 (del32) gene polymorphism in patients with locally advanced breast cancer (LABC) of various molecular subtypes and its effect on the effectiveness of perioperative chemotherapy. Materials and methods. Treatment results of 62 patients with breast cancer stages T1-3N0-3M0 treated with neoadjuvant chemotherapy were evaluated. Results. The role of chemokine receptor CC gene polymorphism (CCR5) (del32) in the efficacy of preoperative chemotherapy in 62 patients with Her2/neu-negative locally advanced breast cancer has been insufficiently studied, genome CCR5. However, the results obtained require further research. Conclusions. The level of therapeutic pathomorphosis after perioperative chemotherapy was better in carriers of N/del132 genotype of CCR5 gene compared with the carriers of N/N genotype of CCR5 gene(p=0,04). The one patient with del132/del132 genotype achieved a pCR after perioperative chemotherapy.
Leave a comment